B. Braun News

Product Quick Finder

Choose a category or subcategory

B. Braun acquires Intermedt Medizin & Technik GmbH, a specialist in the preparation of dialysis concentrates

With the full integration of Intermedt Medizin & Technik GmbH into the Group, B. Braun has completed the extensive product portfolio of its B. Braun Avitum division as a systems provider for extracorporeal blood treatment (dialysis).

The fully automated ECOMix mixing system developed by Intermedt enables dialysis centers to prepare the acid concentrates required for hemodialysis in a simple, flexible, and environmentally friendly manner. Since ECOMix links all the individual components of the dialysis system, the overall dialysis process is optimally coordinated and automated. This gives users more time for the actual therapy and patient care. At the same time, mixing the concentrates on site reduces transport emissions and plastic waste, representing an important contribution to sustainable dialysis therapy.

The companies Intermedt and B. Braun have already been acting together as two strong partners in the dialysis market for several years. With the complete acquisition, the Intermedt product portfolio will be permanently integrated into our comprehensive range of products and services for dialysis therapy. This is also our response to the ever-increasing demand from our customers to offer all dialysis products and services from a single source and to optimize dialysis therapy processes through automation and digitalization,” explains Dr. Holger Seeberg, SVP Global Marketing & Sales Avitum and member of the Executive Board of B. Braun Avitum AG.

Christoph Dumschat, Managing Director of Intermedt Medizin & Technik GmbH, adds, “The acquisition of the business shares by B. Braun is securing the global marketing of our outstanding technology and gives our qualified workforce a perspective for the future.”

Intermedt, headquartered in Ostrhauderfehn, Germany, currently employs 22 people. There will be no significant changes for the employees, as Intermedt will continue to exist independently within the B. Braun Group.

Dialysis therapy and B. Braun

Patients with chronic kidney failure usually need dialysis therapy three times a week, as urine production and the components of urine – i.e. water and waste products – accumulate in the body and, without therapy, urine poisoning (uremia) can develop. In so-called blood washing (hemodialysis), all the blood is purified with the help of a special filter (dialyzer). The dialyzer enables the targeted exchange of water and waste products with the components of a fresh dialysis fluid suitable for the patient, which is prepared from acidic dialysis concentrate.

B. Braun Avitum AG operates a network of more than 360 dialysis centers in Europe, Asia-Pacific, Latin America and Africa and five home care organizations in Europe. In total, they care for around 30,000 patients.